Axonal degeneration is mediated by the mitochondrial permeability transition pore.
Sebastian A Barrientos, Nicolas W Martinez, Soonmoon Yoo...
https://pubmed.ncbi.nlm.nih.gov/21248121/Actively Recruiting
Led by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · Updated on 2025-12-08
400
Participants Needed
4
Research Sites
N/A
Total Duration
Researchers are investigating amyotrophic lateral sclerosis ALS, a severe neurodegenerative disease characterized by motor neuron degeneration and no current cure. This study aims to discover new, reliable biomarkers and understand ALS mechanisms by analyzing changes in peripheral nerve tissue. The research focuses on early pathological events in ALS, including damage to motor axons and neuromuscular connections, using a novel PNS perspective to reveal cell-specific molecular alterations in nerve tissue during disease progression. The study involves analyzing human nerve biopsies from living ALS patients collected during diagnostic procedures, combined with data from preclinical mouse models. This approach will help identify protein biomarkers linked to early disease stages. The researchers will study various cell types within peripheral nerves, such as Schwann cells and macrophages, to understand their role in ALS pathology. Skin biopsies will be used to detect deregulated nerve signatures, and candidate molecular targets will be screened in biofluids from ALS patients and individuals at genetic risk. Participants include ALS patients, neuropathy patients, presymptomatic individuals, healthy controls, and patients with other neurodegenerative diseases. The study measures diagnostic biomarkers over 20 months and evaluates prognostic biomarkers and therapeutic targets over 24 months. Participants will undergo clinical assessments, biopsies, and biofluid sampling. This observational study is conducted under medical supervision to improve ALS diagnosis and treatment development by uncovering early disease markers and mechanisms.
CONDITIONS
Translating Single-cell Vulnerability Into Novel ALS Biomarkers and Therapeutic Targets: Towards a Liquid Nerve Biopsy
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Lead Sponsor
Azienda Ospedaliero Universitaria di Cagliari
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 20 months
Participants undergo assessments to identify ALS biomarkers through minimally invasive skin biopsies and biofluid screening.
Periodic visits depending on cohort assignment
Duration - Up to 24 months
Participants are observed to track prognostic biomarkers and potential therapeutic targets over time.
Periodic visits depending on cohort assignment
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
5
Have more questions? Get in touch with our team for quick support
Sebastian A Barrientos, Nicolas W Martinez, Soonmoon Yoo...
https://pubmed.ncbi.nlm.nih.gov/21248121/M Nolano, V Provitera, F Manganelli...
https://pubmed.ncbi.nlm.nih.gov/27288647/Valeria Casiraghi, Ilaria Milone, Alberto Brusati...
https://pubmed.ncbi.nlm.nih.gov/39241471/Nilo Riva, Sandro Iannaccone, Massimo Corbo...
https://pubmed.ncbi.nlm.nih.gov/21280090/Mariana C Rocha, Paula A Pousinha, Alexandra M Correia...
https://pubmed.ncbi.nlm.nih.gov/24040091/Alexandre Brodovitch, José Boucraut, Emilien Delmont...
https://pubmed.ncbi.nlm.nih.gov/33436881/Francesco Gentile, Stefania Scarlino, Yuri Matteo Falzone...
https://pubmed.ncbi.nlm.nih.gov/31293369/Lindsey R Fischer, Deborah G Culver, Philip Tennant...
https://pubmed.ncbi.nlm.nih.gov/14736504/Nilo Riva, Ferdinando Clarelli, Teuta Domi...
https://pubmed.ncbi.nlm.nih.gov/27982123/Nilo Riva, Francesco Gentile, Federica Cerri...
https://pubmed.ncbi.nlm.nih.gov/35076694/Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Lead Sponsor
Azienda Ospedaliero Universitaria di Cagliari
Collaborating Sponsor